Abstract
Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.
Keywords: Psoriasis area severity index, lymphocyte-function associated antigen-3, memory T cells, Alopecia areata, Quality of life
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Alefacept
Volume: 6 Issue: 3
Author(s): Mustafa Turhan Sahin
Affiliation:
Keywords: Psoriasis area severity index, lymphocyte-function associated antigen-3, memory T cells, Alopecia areata, Quality of life
Abstract: Alefacept is a fully human fusion protein, being the first biologic agent approved for the treatment of chronic, moderate to severe plaque-type psoriasis. Its dual mechanism of action involves inhibition of T-cell activation and selective reduction of memory T cells. It has a slow onset of action, peaking approximately 18 weeks after the first injection. However, it is associated with long remissions without the need for maintenance therapy in psoriatic patients and its efficacy improves with subsequent courses with a high safety profile. The mechanism of action, the results of the clinical trials, its efficacy, pharmacodynamic effects on circulating lymphocytes, and safety and tolerability of alefacept are summarized in this review. Current treatment guidelines are also presented.
Export Options
About this article
Cite this article as:
Mustafa Turhan Sahin , Alefacept, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368229
DOI https://dx.doi.org/10.2174/187152307781368229 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Lung Defence Mechanisms and Their Potential Role in the Prevention of Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews Biomarkers of Acute Kidney Injury in Critical Care Medicine: A Literature Review Based on Recent Patent Applications
Recent Patents on Biomarkers Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations
Current Pharmaceutical Design Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology The Application of Micro-Analytical Techniques to Biomedical Analysis
Current Pharmaceutical Analysis Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets